EnGene squares up to J&J
New detalimogene bladder cancer data send the minnow’s stock up 47%.
ESMO 2025 – J&J brings a new Rybrevant use into the fold
After promising early data in head and neck, J&J plans a new phase 3, Origami-5.
J&J claims a Tecvayli/Darzalex combo win
The company has seen a PFS and OS benefit in the phase 3 Majestec-3 trial.
Astra and J&J tussle over first-line lung
The companies clash over survival curve similarities – and differences.
J&J goes straight into phase 3 in prostate
The company is to test its KLK2-targeting pasritamig in a late-line setting.
J&J’s bladder hope gets its first approval
Inlexzo gets the nod in BCG-unresponsive non-muscle invasive bladder cancer, but the group has bigger plans.
World Lung 2025 – crossing curves in lung cancer
Tolerability could decide first-line therapy in EGFRm disease.
